Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governme… Read more
Evolutionary Genomics Inc (FNAM) - Net Assets
Latest net assets as of December 2022: $-5.59 Million USD
Based on the latest financial reports, Evolutionary Genomics Inc (FNAM) has net assets worth $-5.59 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.35 Million) and total liabilities ($7.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.59 Million |
| % of Total Assets | -237.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | -488.58% |
| 10-Year Change | N/A |
| Growth Volatility | 96.16 |
Evolutionary Genomics Inc - Net Assets Trend (2009–2022)
This chart illustrates how Evolutionary Genomics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Evolutionary Genomics Inc (2009–2022)
The table below shows the annual net assets of Evolutionary Genomics Inc from 2009 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-1.57 Million | +64.36% |
| 2021-12-31 | $-4.40 Million | -140.98% |
| 2020-12-31 | $-1.83 Million | -447.12% |
| 2019-12-31 | $-333.73K | -182.69% |
| 2018-12-31 | $403.59K | -71.25% |
| 2017-12-31 | $1.40 Million | -23.77% |
| 2016-12-31 | $1.84 Million | -36.88% |
| 2015-12-31 | $2.92 Million | +116.94% |
| 2014-12-31 | $1.34 Million | +1842.46% |
| 2013-12-31 | $-77.17K | -23.24% |
| 2012-12-31 | $-62.62K | -29.11% |
| 2011-12-31 | $-48.50K | -55.65% |
| 2010-12-31 | $-31.16K | -308.31% |
| 2009-12-31 | $-7.63K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evolutionary Genomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1861152300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.66K | % |
| Other Components | $18.24 Million | % |
| Total Equity | $-1.57 Million | 100.00% |
Evolutionary Genomics Inc Competitors by Market Cap
The table below lists competitors of Evolutionary Genomics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Torah Cement
EGX:TORA
|
$1.33K |
|
ConectiSys Corporation
PINK:CONC
|
$1.33K |
|
Life Is Hard SA
RO:LIH
|
$1.33K |
|
Arcontech Group Plc
LSE:ARC
|
$1.33K |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
$1.33K |
|
Conn's, Inc.
NASDAQ:CONNQ
|
$1.33K |
|
Sterling Consolidated Corp
PINK:STCC
|
$1.33K |
|
Block Energy PLC
LSE:BLOE
|
$1.33K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evolutionary Genomics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -4,400,116 to -1,568,277, a change of 2,831,839.
- Net loss of 1,934,967 reduced equity.
- New share issuances of 1,004,004 increased equity.
- Other factors increased equity by 3,762,802.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.93 Million | -123.38% |
| Share Issuances | $1.00 Million | +64.02% |
| Other Changes | $3.76 Million | +239.93% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evolutionary Genomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $-0.07 | $0.00 | x |
| 2010-12-31 | $-0.24 | $0.00 | x |
| 2011-12-31 | $-0.37 | $0.00 | x |
| 2012-12-31 | $-0.48 | $0.00 | x |
| 2013-12-31 | $-0.60 | $0.00 | x |
| 2014-12-31 | $-0.11 | $0.00 | x |
| 2015-12-31 | $0.59 | $0.00 | x |
| 2016-12-31 | $0.31 | $0.00 | x |
| 2017-12-31 | $0.24 | $0.00 | x |
| 2018-12-31 | $0.07 | $0.00 | x |
| 2019-12-31 | $-0.06 | $0.00 | x |
| 2020-12-31 | $-0.31 | $0.00 | x |
| 2021-12-31 | $-0.75 | $0.00 | x |
| 2022-12-31 | $-0.24 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evolutionary Genomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-27.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.26K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.41K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.49K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.77K |
| 2013 | 0.00% | -2.41% | 806.28x | 0.00x | $-11.54K |
| 2014 | 0.00% | -7.80% | 0.26x | 0.00x | $-25.77K |
| 2015 | -9.80% | -108.78% | 0.08x | 1.09x | $-577.71K |
| 2016 | -62.56% | -519.91% | 0.03x | 3.48x | $-1.34 Million |
| 2017 | -38.44% | -1650.71% | 0.01x | 3.85x | $-679.98K |
| 2018 | -272.21% | -956.87% | 0.03x | 10.87x | $-1.14 Million |
| 2019 | 0.00% | -646.48% | 0.03x | 0.00x | $-759.77K |
| 2020 | 0.00% | -13695.06% | 0.00x | 0.00x | $-1.53 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.35 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.78 Million |
Industry Comparison
This section compares Evolutionary Genomics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evolutionary Genomics Inc (FNAM) | $-5.59 Million | 0.00% | N/A | $1.33K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |